A mother in a critical condition has successfully raised over £50,000 from public donations following an appeal in the Mirror to secure funding for the Enhertu drug, which could prolong her life. Jess Duggan, 44, expressed gratitude for the overwhelming support she received, describing it as remarkable. With the funds raised, she was able to receive her first dose of the drug and cherish special moments with her children, hoping to witness her son’s upcoming 13th birthday.
The lack of accessibility to the Enhertu drug for women with breast cancer in certain parts of the UK has sparked outrage, with Jess and many others being denied access while it remains freely available in Scotland and other European countries. A survey conducted by Breast Cancer Now revealed that 82% of UK adults believe that this life-extending treatment should be accessible through the NHS.
Despite facing a grim prognosis, Jess remains resilient in advocating for the drug to be included in NHS funding. She emphasized the importance of public support and urged Health Secretary Yvette Cooper to push for the drug’s approval. The funding for her treatment has highlighted the public’s stance on the issue and the necessity for the drug to be financially supported by the NHS.
Having recently celebrated her daughter’s 16th birthday, Jess shared the emotional toll of having to inform her children about her limited time left. She expressed frustration at the unavailability of the drug through NHS channels, stressing that earlier access could have significantly altered her current situation. Jess’s crowdfunding success has enabled her to afford multiple doses of the drug, offering hope for a prolonged life expectancy.
The ongoing battle for access to Enhertu has drawn attention to the struggles faced by individuals with metastatic breast cancer. Organizations like Breast Cancer Now are actively campaigning for broader access to the drug, emphasizing the urgent need for its availability. The current stance from National Institute for Health and Care Excellence (NICE) reflects the ongoing discussions surrounding the cost-effectiveness of the treatment and the potential for a revised decision.
Jess’s journey highlights the challenges faced by individuals navigating treatment options and funding constraints. Her determination and the outpouring of support from the public underscore the significance of making life-extending treatments more accessible to those in need.
